Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

161. Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review

Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC (...) . Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severely active Crohn's disease Authors' conclusions Adalimumab (Humira) is a fully human anti-tumour necrosis factor (TNF)-alpha monoclonal antibody in phase III trials for the induction and maintenance of clinical remission

2005 Health Technology Assessment (HTA) Database.

162. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden (Full text)

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Bansback N J, Brennan A, Ghatnekar O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of adalimumab (40mg/week), a fully human monoclonal antibody with high affinity and specificity for tumour necrosis factor (TNF), for the treatment of moderate to severe rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-utility analysis. Study

2005 NHS Economic Evaluation Database. PubMed

163. Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review

Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review Adalimumab (Humira) for moderate to severe psoriatic arthritis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Adalimumab (...) (Humira) for moderate to severe psoriatic arthritis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2004 Authors' objectives This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severe psoriatic arthritis. Authors' conclusions Adalimumab (Humira) is a fully human anti-TNF-a monoclonal antibody in phase III trials for reducing the signs and symptoms of active psoriatic arthritis (PsA) in adults. It is anticipated

2004 Health Technology Assessment (HTA) Database.

164. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab (...) when added to methotrexate in patients with active rheumatoid arthritis Hochberg M C, Tracy J K, Hawkins-Holt M, Flores R H CRD summary This review compared adalimumab, etanercept and infliximab when added to methotrexate in patients with active rheumatoid arthritis. The authors concluded that the three agents have similar efficacy when combined with methotrexate. Overall, the methods of analysis may mean that the trials were not powered to detect any true treatment effect differences. Head-to-head

2003 DARE.

165. Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate

Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate Adalimumab (Humira®) - For the treatment of moderate to severe, active (...) rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Adalimumab (Humira®) - For the treatment of moderate to severe, active rheumatoid arthritis

2003 Health Technology Assessment (HTA) Database.

166. Adalimumab

Adalimumab Adalimumab Adalimumab Stachnik J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Stachnik J. Adalimumab. University HealthSystem Consortium (UHC). Drug Monograph. 2002 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug information

2002 Health Technology Assessment (HTA) Database.